These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 26640901)

  • 41. A Follow-Up Study on the Renal Protective Efficacy of Telbivudine for Hepatitis B Virus-Infected Taiwanese Patients After Living Donor Liver Transplant.
    Lin KH; Chen YL; Lin PY; Hsieh CE; Ko CJ; Lin CC; Ming YZ
    Exp Clin Transplant; 2017 Feb; 15(1):65-68. PubMed ID: 28004999
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Recurrence of hepatitis C virus (genotype 4) infection after living-donor liver transplant in Egyptian patients.
    Yosry A; Abdel-Rahman M; Esmat G; El-Serafy M; Omar A; Doss W; Zayed N; Said M; Ismail T; Hosny A; Marawan E; El-Malt O; Kamel RR; Hatata Y; El-Taweel A; Ghali A; Sabri H; Kamel S; El-Gabaly H
    Exp Clin Transplant; 2009 Sep; 7(3):157-63. PubMed ID: 19715525
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The Long-Term Effect of Hepatitis C Virus on the Outcome of Live-Donor Kidney Transplant Recipients. A Retrospective Study.
    Denewar AA; Monem El-Hendy YA; Wafa EW; Ghorab AA; Sheashaa HA; Rashad RH; Nagib AM; Neamatallah AH; Abbas MH; Shokeir AA
    Exp Clin Transplant; 2015 Oct; 13(5):402-7. PubMed ID: 26450463
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Concise review: Interferon-free treatment of hepatitis C virus-associated cirrhosis and liver graft infection.
    Weiler N; Zeuzem S; Welker MW
    World J Gastroenterol; 2016 Nov; 22(41):9044-9056. PubMed ID: 27895394
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Impact of Donor Hepatitis C Virus on Kidney Transplant Outcomes for Hepatitis C-positive Recipients in the Direct-acting Antiviral Era: Time to Revise the Kidney Donor Risk Index?
    Cannon RM; Locke JE; Orandi BJ; Anderson DJ; Davis EG; Mackelaite L; Dave H; Eng M; Jones CM
    Transplantation; 2020 Jun; 104(6):1215-1228. PubMed ID: 31517783
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Use of Elderly Allografts in Liver Transplantation.
    Paterno F; Wima K; Hoehn RS; Cuffy MC; Diwan TS; Woodle SE; Abbott DE; Shah SA
    Transplantation; 2016 Jan; 100(1):153-8. PubMed ID: 26154390
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Current management and perspectives for HCV recurrence after liver transplantation.
    Coilly A; Roche B; Samuel D
    Liver Int; 2013 Feb; 33 Suppl 1():56-62. PubMed ID: 23286847
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Transplant of Kidneys From Hepatitis C Virus-Positive Donors To Hepatitis C Virus-Negative Recipients: A Retrospective Study and Systematic Review.
    Shadekejiang H; Zhu J; Wu X
    Exp Clin Transplant; 2022 Dec; 20(12):1076-1084. PubMed ID: 36718006
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Adult Liver Allocation in Eurotransplant.
    Jochmans I; van Rosmalen M; Pirenne J; Samuel U
    Transplantation; 2017 Jul; 101(7):1542-1550. PubMed ID: 28060242
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Opportunities for scientific expansion of the deceased donor pool.
    Matton AP; Porte RJ
    Liver Transpl; 2014 Nov; 20 Suppl 2():S5. PubMed ID: 25219379
    [No Abstract]   [Full Text] [Related]  

  • 51. A Closing Chapter: Hepatitis C Genotype 3 Elimination in Liver Transplant; Sofosbuvir/Daclatasvir in a Hard-to-Treat Population.
    Teegen EM; Globke B; Schott E; Pratschke J; Eurich D
    Exp Clin Transplant; 2018 Feb; 16(1):61-67. PubMed ID: 29137590
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Dropout rate from the liver transplant waiting list because of hepatocellular carcinoma progression in hepatitis C virus-infected patients treated with direct-acting antivirals.
    Zanetto A; Shalaby S; Vitale A; Mescoli C; Ferrarese A; Gambato M; Franceschet E; Germani G; Senzolo M; Romano A; Angeli P; Rugge M; Farinati F; Forton DM; Cillo U; Burra P; Russo FP
    Liver Transpl; 2017 Sep; 23(9):1103-1112. PubMed ID: 28544587
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The donor risk index: A decade of experience.
    Flores A; Asrani SK
    Liver Transpl; 2017 Sep; 23(9):1216-1225. PubMed ID: 28590542
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Changes in Utilization and Discard of HCV Antibody-Positive Deceased Donor Kidneys in the Era of Direct-Acting Antiviral Therapy.
    Bowring MG; Kucirka LM; Massie AB; Ishaque T; Bae S; Shaffer AA; Garonzik Wang J; Sulkowski M; Desai N; Segev DL; Durand CM
    Transplantation; 2018 Dec; 102(12):2088-2095. PubMed ID: 29912046
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The effect of pretransplant chronic hepatitis C virus infection treatment on graft and patient survival in renal transplant recipients.
    Korkmaz M; Fakı S; Öcal S; Harmancı Ö; Ensaroğlu F; Selçuk H; Haberal M
    Exp Clin Transplant; 2015 Apr; 13 Suppl 1():188-92. PubMed ID: 25894152
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Hepatitis C Virus Recurrence Occurs Earlier in Patients Receiving Donation After Circulatory Death Liver Transplant Grafts Compared With Those Receiving Donation After Brainstem Death Grafts.
    Townsend SA; Monga MA; Nightingale P; Mutimer D; Elsharkawy AM; Holt A
    Transplant Proc; 2017 Nov; 49(9):2129-2134. PubMed ID: 29149973
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparative analysis of hepatitis C recurrence and fibrosis progression between deceased-donor and living-donor liver transplantation: 8-year longitudinal follow-up.
    Jain A; Singhal A; Kashyap R; Safadjou S; Ryan CK; Orloff MS
    Transplantation; 2011 Aug; 92(4):453-60. PubMed ID: 21799468
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Allografts positive for hepatitis B surface antigen in liver transplant for disease related to hepatitis B virus.
    Ju W; Chen M; Guo Z; Wang D; Zhu X; Huang J; He X
    Exp Clin Transplant; 2013 Jun; 11(3):245-9. PubMed ID: 23176583
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cytomegalovirus infection in living donor liver transplant recipients significantly impacts the early post-transplant outcome: A single center experience.
    Yadav SK; Saigal S; Choudhary NS; Saha S; Sah JK; Saraf N; Kumar N; Goja S; Rastogi A; Bhangui P; Soin AS
    Transpl Infect Dis; 2018 Aug; 20(4):e12905. PubMed ID: 29668120
    [TBL] [Abstract][Full Text] [Related]  

  • 60. HLA tissue typing has no effect on the outcome of patients undergoing a living-donor liver transplant: a single-center experience in Egypt.
    Yosry A; Said M; Esmat G; Al-Serafy M; Omar A; Doss W; Omran D; Saad Y; Kamel S; Abdel-Bary A; Hatata Y; Hosny A
    Exp Clin Transplant; 2012 Apr; 10(2):136-40. PubMed ID: 22432757
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.